Form 8-K - Current report:
SEC Accession No. 0000886163-21-000127
Filing Date
2021-11-09
Accepted
2021-11-09 16:06:42
Documents
14
Period of Report
2021-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lgnd-20211109.htm   iXBRL 8-K 33670
2 EX-99.1 q32021earningsreleaseex99_1.htm EX-99.1 194241
6 image1.jpg GRAPHIC 36525
  Complete submission text file 0000886163-21-000127.txt   437543

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lgnd-20211109.xsd EX-101.SCH 1909
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lgnd-20211109_lab.xml EX-101.LAB 24132
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lgnd-20211109_pre.xml EX-101.PRE 12516
7 EXTRACTED XBRL INSTANCE DOCUMENT lgnd-20211109_htm.xml XML 10769
Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

EIN.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33093 | Film No.: 211392102
SIC: 2834 Pharmaceutical Preparations